ReviewImmunology2018
Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering.
Review in Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- A single polypeptide vaccine derived from multiple antigens confers protection against staphylococcus aureus infection in mice.Tropical diseases, travel medicine and vaccines · 2026Article
- Mechanisms of angiopoietin-like protein 7 regulation and therapeutic potential in tumors.Molecular biology reports · 2026Review
- Rapid Screening and Effective Rabbit-Derived Fab Antibodies Production Based on Yeast Surface Display.Combinatorial chemistry & high throughput screening · 2026Article
- Review
- Machine learning-based construction of an oxidative stress-related model reveals molecular subtypes and tumor microenvironment infiltration signatures in colon cancer.Discover oncology · 2025Article
- Identification of a novel diagnostic biomarker for osteoarthritis associated with chromatin regulators based on bioinformatics and experiments.Journal of orthopaedic surgery and research · 2025Article
- Integrative analysis and prognostication in gastric cancer: unveiling the role of mitochondrial genomics with the MLRScore model.Discover oncology · 2025Article
- Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.Signal transduction and targeted therapy · 2025Review
- FASTIA: A rapid and accessible platform for protein variant interaction analysis demonstrated with a single-domain antibody.Protein science : a publication of the Protein Society · 2025Article
- Protein recognition methods for diagnostics and therapy.BBA advances · 2025Review
- Analysis of the basement membrane-related genes ITGA7 and its regulatory role in periodontitis via machine learning: a retrospective study.BMC oral health · 2024Article
- Analysis and identification of ferroptosis-related diagnostic markers in rheumatoid arthritis.Annals of medicine · 2024Article
- Artificial Intelligence in Point-of-Care Biosensing: Challenges and Opportunities.Diagnostics (Basel, Switzerland) · 2024Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Peptide Antibodies: Current Status.Methods in molecular biology (Clifton, N.J.) · 2024Article
- RNA nanostructures for targeted drug delivery and imaging.RNA biology · 2024Review
- SPRR1B is Related to the Immune Microenvironment and Can Be Used as a Biomarker for the Diagnosis of Psoriasis.International journal of general medicine · 2024Article
- Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses.PLoS pathogens · 2023Article
- Identification of basement membrane-related biomarkers associated with the diagnosis of osteoarthritis based on machine learning.BMC medical genomics · 2023Article
- Genotyped functional screening of soluble Fab clones enables in-depth analysis of mutation effects.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibody discovery and engineering is a field that has traditionally been dominated by high-throughput screening platforms (e.g. hybridomas and surface display). In recent years the emergence of high-throughput sequencing has made it possible to obtain large-scale information on antibody repertoire diversity. Additionally, it has now become more routine to perform high-throughput sequencing on antibody repertoires to also directly discover antibodies. In this review, we provide an overview of the progress in this field to date and show how high-throughput screening and sequencing are converging to deliver powerful new workflows for monoclonal antibody discovery and engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.